Prof. Marcy Zenobi-Wong is a Full Professor at ETH Zurich's Department of Health Sciences and Technology, specializing in biofabrication and tissue engineering. Her research focuses on cartilage regeneration using advanced biomaterials, including nanofilm coatings and 3D printing techniques. She holds patents in tissue engineering and has pioneered methods like filamented light (FLight) biofabrication for creating anisotropic tissues. Her academic journey includes a B.Sc. from MIT (1985), M.Sc. and Ph.D. from Stanford (1987, 1990), followed by postdoctoral work at the University of Michigan. She leads the Biofabrication Group at ETH, developing therapies for joint repair and regenerative medicine. Courses taught include Biomedical Engineering and Materials and Mechanics in Medicine . Research highlights include engineered hydrogels for cartilage protection, CRISPR-driven gene editing in chondrocytes, and biohybrid neural interfaces. Her work bridges material science, cell biology, and clinical applications, with a focus on translational medicine. Collaborative projects involve creating elastic cartilage grafts for microtia reconstruction and volumetric printing of complex tissue constructs.
Vivek Shenoy is the Eduardo D. Glandt President's Distinguished Professor at the University of Pennsylvania, with primary appointments in the Department of Materials Science and Engineering and secondary appointments in Bioengineering and Mechanical Engineering and Applied Mechanics. He leads the Multiscale Mechanobiology and Biomaterials Laboratory, which focuses on developing theoretical frameworks and numerical methods to understand complex biological and engineering systems across multiple length scales. Shenoy's research spans mechanobiology, chromatin organization, cell mechanics, and biomaterials. His work addresses the fundamental challenge of modeling how small-scale cellular phenomena couple with long-range tissue-level interactions across micrometers to centimeters. By integrating insights from soft matter physics, solid mechanics, chemistry, and applied mathematics, his group develops multiphysics continuum and mesoscale theories to elucidate mechanisms controlling both biological and engineering systems. His recent publications demonstrate an increasing focus on nuclear mechanics, chromatin organization, and the interplay between mechanical forces and gene regulation. Analysis of Shenoy's publication record reveals a strong interdisciplinary approach, with high-impact papers spanning biophysics, materials science, and cell biology. His work shows consistent evolution from fundamental mechanics of materials to complex biological systems, with recent emphasis on the mechanical regulation of chromatin architecture, cell migration dynamics in 3D environments, and mechanotransduction in development and disease. His publications appear regularly in top journals including Nature, Science, and their affiliated publications, demonstrating significant influence across multiple fields. Eduardo D. Glandt President's Distinguished Professor Multiple publications in Nature, Science, and PNAS Active research program with publications through 2025 Shenoy actively mentors students and postdocs through his laboratory, with numerous co-authored publications indicating strong mentorship. His research program appears to be well-funded through multiple grants supporting his work in mechanobiology and biomaterials. The Multiscale Mechanobiology and Biomaterials Laboratory maintains active collaborations across disciplines and institutions, reflecting the interdisciplinary nature of his research. The Multiscale Mechanobiology and Biomaterials Laboratory, housed within the Department of Materials Science and Engineering at the University of Pennsylvania, serves as the primary research hub for Shenoy's work. The lab maintains an active presence on social media (Twitter: @ShenoyLab) for updates on activities and publications. Their research approach combines theoretical modeling with experimental validation to address fundamental questions at the interface of mechanics, materials science, and biology.
Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.
Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Chi Liu is a Professor of Radiology & Biomedical Imaging at Yale School of Medicine . He serves as Associate Director of Biomedical Imaging Technology at the Yale Biomedical Imaging Institute and Director for Research Faculty Affairs in the Radiology & Biomedical Imaging department. Education : PhD from Johns Hopkins University (2008) Postdoctoral Training : University of Washington (2010) Certification : American Board of Science in Nuclear Medicine (Nuclear Medicine Physics and Instrumentation) His research focuses on quantitative cardiac and oncological PET/CT and SPECT/CT imaging , emphasizing deep learning algorithms , reconstruction algorithms , data correction , and dynamic imaging . Key clinical applications include early detection of chemotherapy-induced cardiotoxicity , multimodality imaging of heart failure , and motion variability elimination in therapy response assessment . The 15 most recent publications reveal a strong emphasis on deep learning techniques for low-dose imaging , motion correction , and cross-tracer generalizability in PET/SPECT systems. These works span applications in cardiac imaging , neuroscience , oncology , and theranostics . Scientific Award : Bruce Hasegawa Young Investigator Medical Imaging Science Award (2012) Contact: chi.liu@yale.edu | ORCID 0000-0002-7007-1037
Prof. Abbas Samani is a Professor at the Department of Electrical and Computer Engineering and holds a joint appointment in the Department of Medical Biophysics at Western University . He is a core faculty member of the Biomedical Engineering Graduate Program and an Associate Scientist at Imaging Research Laboratories of Robarts Research Institute . His academic journey includes a Ph.D. from the University of Waterloo, an M.Sc. from the University of Tehran, and a B.Sc. from Amirkabir University of Technology. His research focuses on biological tissue computational modeling and its applications in medical imaging, intervention, and image analysis . He develops computer/image-assisted tools for minimally invasive disease diagnosis and therapy , targeting heart disease, cancer, and lung disease . Key projects include myocardium biomechanical modeling , handheld medical devices for breast cancer screening , and lung disease diagnostics via CT image segmentation . His recent publications emphasize ultrasound elastography , finite element modeling , and inverse problems in biomechanics , primarily in journals like IEEE Transactions on Computational Imaging and Translational Oncology . His work spans both computational modeling and medical device development . Selected Graduate Supervision : Ph.D. Candidates : Seyed Hassan Haddad, Elham Karami, Seyed Mohammad Hesabgar Graduated Ph.D. Students : Ali Sadeghi Naini, Seyed Reza Mousavi M.Sc. Students : Cristian Linte, Patrick Courtis, Joseph O'Hagan, Hatef Mehrabian, Hirad Karimi, Hosein Amooshahi, Seyed Mohammad Hesabgar, Nastaran Ghadarghadr, Shadi Shavakh, Ehsan Salamati, Ehsan Omidi Teaching Contributions : Graduate: BME9519B/CAMI9519B/ECE9202B/ECE9022B - Advanced Image Processing and Analysis , MBP9530A - Human Biomechanics and Biomedical Applications Undergraduate: ECE4438B - Advanced Image Processing and Analysis , ES1050 - Introductory Engineering Design and Innovation Studio , MBP3330F - Human Biomechanics and Biomedical Applications Research Affiliations : Robarts Research Institute - Associate Scientist at Imaging Research Laboratories Western University - Core Faculty, Biomedical Engineering Graduate Program
Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.
Dr. William V. Giannobile serves as the Dean and A. Lee Loomis, Jr. Professor of Oral Medicine, Infection, and Immunity at Harvard School of Dental Medicine (HSDM). He leads the institution as its chief academic and administrative officer while maintaining an active research program and clinical practice in periodontics and implant dentistry at the Harvard Dental Center in Cambridge, MA. Dr. Giannobile received his DDS and MS in oral biology from the University of Missouri, followed by a certificate in periodontology and Doctor of Medical Sciences (DMSc) in oral biology from Harvard School of Dental Medicine. He completed postdoctoral training in molecular biology at the Dana-Farber Cancer Institute and Harvard Medical School. With over 30 years of continuously NIH-funded research, Dr. Giannobile's work focuses on oral and periodontal regenerative medicine, tissue engineering, and precision medicine. He serves as principal investigator of the NIDCR U-Award Harvard Clinical Practice-based Research Program for Dental Students (H-CREDENT), which evaluates the genomics of oral pain in a multi-institutional academic setting. His research has produced over 300 manuscripts, textbook chapters, and patents focused on periodontology, regenerative medicine, and oral health research. He has edited or co-edited over 10 books in clinical and translational research, periodontology, and regenerative medicine. His publications demonstrate consistent focus on periodontal regeneration, biomaterials, tissue engineering, and the molecular mechanisms underlying oral diseases. ADA Gold Medal Award for Excellence in Dental Research (2024) International Association for Dental Research Distinguished Scientist Research in Periodontal Disease Award (2022) Norton M. Ross Clinical Research Award from the American Dental Association (2018) William J. Gies Award (2014) Jan Lindhe International Periodontology Research Award (2011) As an educator and mentor, Dr. Giannobile completed a 10-year term as editor-in-chief for the Journal of Dental Research, the official journal of the International Association for Dental Research. He has served as a consultant to the U.S. Food and Drug Administration for Dental Devices and as an associate editor for the NIDCR Report on Oral Health of the U.S. in 2021. His laboratory continues to advance research in periodontal regeneration and precision medicine approaches to oral health, with ongoing NIH funding supporting innovative translational research.
